ABBV
AbbVie Inc.
Is ABBV Halal?
Medicines are generally beneficial and permissible, but AbbVie's March 2026 total-assets financial screens fail because interest-bearing debt is 53.39% of assets.
What You Should Know
AbbVie develops medicines and products across immunology, neuroscience, oncology, eye care, aesthetics and other specialties. Its current liquidity, receivables and disclosed-interest ratios pass, but debt exceeds every examined total-assets limit. Product-level formulations, ingredients, cell lines, research inputs, licensing and use-specific aesthetics revenue are not disclosed as a Sharia-screened numerator, so ZakatInvest classifies ABBV as doubtful rather than erasing the beneficial core business or claiming universal non-compliance.
⚠️ Concerns
- •Interest-bearing debt is 53.39% of total assets
- •Product-specific ingredients, excipients, biologic inputs, cell lines and manufacturing require evidence
- •Disclosed gross interest income was 0.48% of quarterly revenue
- •Animal research and validated replacement, reduction and refinement alternatives
- •Drug safety, clinical trials, pricing, patents, access, marketing and litigation
- •Aesthetic-product use, body-image ethics, supply chain, labor, privacy and environmental impacts
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-12.
72,858 / 136,463
9,421 / 136,463
21,870 / 136,463
72 / 15,002
- Financial
- Fails
- Overall
- Fails
Debt is 53.39% of total assets and exceeds the 33.333% limit. Identifiable liquidity is 6.90%, receivables plus cash is 16.03%, and disclosed gross interest income is 0.48%; those ratios pass, but the debt failure determines the financial result.
- Financial
- Fails
- Overall
- Fails
Debt is 53.39% and exceeds the examined 33.33% total-assets limit. Liquidity and receivables-plus-cash pass, but the debt failure determines the result; the product- and use-level business screen remains incomplete.
- Financial
- Fails
- Overall
- Fails
Debt is 53.39% and exceeds the examined 33% total-assets limit. This is a calculation against the SAC ratios, not an official SAC classification of a U.S.-listed security; screened product revenue is unavailable.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible 24- or 36-month issuer market-cap history is not yet stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
AbbVie researches, develops and commercializes medicines and products across immunology, neuroscience, oncology, eye care, aesthetics and other specialties. Treating serious disease, reducing pain and improving health are generally beneficial and permissible purposes. Medical and aesthetic products still require product- and use-specific review rather than assuming every formulation, input and indication is identical.
Limitation: The filing provides detailed product revenue but does not classify revenue by Sharia-screened formulation, excipient, alcohol carrier, animal-derived or biologic input, cell line, research method, manufacturing process, licensing arrangement, clinical use, or elective aesthetic use. No exact prohibited-revenue percentage can be reproduced from consolidated disclosure.
Purification
Disclosed gross interest income equals 0.48% of quarterly net revenues. Product- and use-level screened operating revenue remains unavailable, so 0.48% is evidence for the income screen rather than a complete fixed purification prescription.
Inputs, assumptions and primary sources
- Interest-bearing debt is the sum of zero short-term borrowings, 8,326 of the current portion of long-term debt and 64,532 of long-term debt using the reported balance-sheet carrying amounts.
- Cash and equivalents use the reported 9,391 balance.
- Identifiable interest-bearing securities are 10 of money-market funds and time deposits plus 20 of debt securities. Public and non-readily-determinable equity securities are excluded from the liquidity numerator.
- Receivables use the reported 12,479 net accounts-receivable balance.
- Net revenues of 15,002 and disclosed gross interest income of 72 use the same three-month period ended March 31, 2026.
- AbbVie discloses revenue by product and therapeutic portfolio, but not as a Sharia-screened numerator by formulation, excipient, biologic input, cell line, research method, manufacturing input, licensing arrangement, clinical use, or aesthetic use.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →